Press Release: Selexys : Cytovance Biologics, Inc. and Selexys Pharmaceuticals, Corp. Announce Development and cGMP Manufacturing Agreement for SELK2 Drug Product

OKLAHOMA CITY, OK--(Marketwired - May 6, 2014) - Cytovance Biologics, Inc., a leading full-service contract manufacturer ("CMO") of mammalian and microbial biologics, announces a development and manufacturing agreement with Selexys Pharmaceuticals, Corp., an Oklahoma City-based clinical stage biopharmaceutical company.�